noobkiller999
Truth, no matter how bitter, is better than a lie
- Joined
- Jan 11, 2024
- Posts
- 2,191
- Reputation
- 2,221
Oxandrolone is a medication used to promote weight gain in various clinical scenarios. Its applications include counteracting protein catabolism induced by long-term corticosteroid therapy, facilitating recovery from severe burns, managing bone pain associated with osteoporosis, and aiding in the development of girls with Turner syndrome.
Differential benefits of steroid therapies in adults following major burn injury: This study compared the effects of oxandrolone and corticosteroids following serious burns. Steroid therapy after severe thermal injury can significantly influence a patient's prognosis. Oxandrolone was associated with superior outcomes, with the exception of multiple organ failure (MOF). When treating burn patients, the side effect profiles of both corticosteroids and oxandrolone must be considered.
As we can observe overall, oxandrolone demonstrated favorable results, including an absence of certain adverse effects typically associated with corticosteroid (CS) use.
Oxandrolone is an FDA-approved drug for use in HIV patients. For instance, in the resource "Oxandrolone for weight gain," we find the following statement:
Is this convincing? It seems quite so. However, our analysis of this steroid's safety profile does not end here. There is a rather interesting study: "Use of Oxandrolone to Promote Growth in Neonates following Surgery for Complex Congenital Heart Disease: An Open-Label Pilot Trial." Indeed, you heard correctly—oxandrolone therapy at the investigated doses appears to be safe for neonates following surgery for complex congenital heart disease (CHD).
Returning to the topic of burns, let us examine another interesting study: "FIVE-YEAR OUTCOMES AFTER LONG-TERM OXANDROLONE ADMINISTRATION IN SEVERELY BURNED CHILDREN: A RANDOMIZED CLINICAL TRIAL." This study included 119 severely burned patients, randomized to a control group (n = 84) and a long-term oxandrolone group (n = 35). Oxandrolone was administered for an average of 16.1 months post-burn (range 12.1–25.2 months).
The researchers conducted numerous measurements, and the conclusions are as follows:
Reviewing the research, "Aspects of the treatment of Turner syndrome":
The low incidence of oxandrolone's side effects is attributed to its strong anabolic and weak androgenic properties. Oxandrolone possesses six times the anabolic activity of testosterone. It was first synthesized in 1962 and introduced for medical use in 1964. Activation of the androgen receptor stimulates protein synthesis, promoting muscle growth, lean body mass, and bone mineral density.
Because oxandrolone is already 5α-reduced, it is not a substrate for the 5α-reductase enzyme and, therefore, is not potentiated in androgen-sensitive tissues such as the skin, hair follicles, and prostate gland.
The substitution of a carbon atom with an oxygen atom at the C2 position in the A ring makes oxandrolone resistant to inactivation by 3α-hydroxysteroid dehydrogenase in skeletal muscle. This contrasts with DHT and is believed to underlie oxandrolone's preserved anabolic activity.
As oxandrolone is 5α-reduced, it is not a substrate for aromatase and therefore cannot be converted into metabolites with estrogenic activity. Oxandrolone also lacks progestogenic activity.
Oxandrolone is uniquely less hepatotoxic than other 17α-alkylated AAS, which may be related to differences in metabolism (The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety).
btw guys i used ai for translation into English so faggots stfu
Differential benefits of steroid therapies in adults following major burn injury: This study compared the effects of oxandrolone and corticosteroids following serious burns. Steroid therapy after severe thermal injury can significantly influence a patient's prognosis. Oxandrolone was associated with superior outcomes, with the exception of multiple organ failure (MOF). When treating burn patients, the side effect profiles of both corticosteroids and oxandrolone must be considered.
As we can observe overall, oxandrolone demonstrated favorable results, including an absence of certain adverse effects typically associated with corticosteroid (CS) use.
Oxandrolone is an FDA-approved drug for use in HIV patients. For instance, in the resource "Oxandrolone for weight gain," we find the following statement:
The statement that the incidence of side effects is significantly lower compared to other anabolic-androgenic steroids (AAS) is particularly encouraging. However, for a community that strives to operate on evidence-based facts, a single claim is insufficient. Therefore, let us refer to this study: "Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study." As you can see, this study meets all the criteria for reliability. From it, we learn the following information:
Let us examine the basis for these conclusions in more detail. As noted above, this was a randomized, double-blind, placebo-controlled trial involving 262 HIV-infected men with confirmed weight loss of 10% to 20%, or a low Body Mass Index. A more detailed look reveals that body weight increased in all groups, including the placebo group, during the double-blind phase. However, at the 12-week mark, only the weight gain in the 40 mg oxandrolone group and the body cell mass (BCM) gain in the 40 mg and 80 mg oxandrolone groups were significantly greater than in the placebo group. Oxandrolone treatment was associated with significant suppression of sex hormone-binding globulin, luteinizing hormone, follicle-stimulating hormone, and total and free testosterone levels. The treatment was generally well-tolerated but was accompanied by significant increases in transaminase and low-density lipoprotein (LDL) levels, as well as a decrease in high-density lipoprotein (HDL) levels.
Is this convincing? It seems quite so. However, our analysis of this steroid's safety profile does not end here. There is a rather interesting study: "Use of Oxandrolone to Promote Growth in Neonates following Surgery for Complex Congenital Heart Disease: An Open-Label Pilot Trial." Indeed, you heard correctly—oxandrolone therapy at the investigated doses appears to be safe for neonates following surgery for complex congenital heart disease (CHD).
Returning to the topic of burns, let us examine another interesting study: "FIVE-YEAR OUTCOMES AFTER LONG-TERM OXANDROLONE ADMINISTRATION IN SEVERELY BURNED CHILDREN: A RANDOMIZED CLINICAL TRIAL." This study included 119 severely burned patients, randomized to a control group (n = 84) and a long-term oxandrolone group (n = 35). Oxandrolone was administered for an average of 16.1 months post-burn (range 12.1–25.2 months).
The researchers conducted numerous measurements, and the conclusions are as follows:
This smoothly leads us to another aspect: bone health, bone mass, or whatever you wish to call it. To analyze the effect of Oxandrolone in this area, we will consider another study: "Cortical Bone Mass is Low in Boys with Klinefelter Syndrome and Improves with Oxandrolone."
To continue, let us explore the potential for treating Turner syndrome, a chromosomal disorder characterized by the complete or partial absence of one X chromosome.
Reviewing the research, "Aspects of the treatment of Turner syndrome":
Let us proceed further; one study is not enough. Let us examine this one: "Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome: evidence from recent studies and recommendations for use." Its conclusions are drawn from three studies:
Although we have established above that oxandrolone's side effects are relatively infrequent, they can include masculinization, acne, hirsutism, voice changes, and increased libido. Information on such effects is documented by the FDA.
The low incidence of oxandrolone's side effects is attributed to its strong anabolic and weak androgenic properties. Oxandrolone possesses six times the anabolic activity of testosterone. It was first synthesized in 1962 and introduced for medical use in 1964. Activation of the androgen receptor stimulates protein synthesis, promoting muscle growth, lean body mass, and bone mineral density.
Because oxandrolone is already 5α-reduced, it is not a substrate for the 5α-reductase enzyme and, therefore, is not potentiated in androgen-sensitive tissues such as the skin, hair follicles, and prostate gland.
The substitution of a carbon atom with an oxygen atom at the C2 position in the A ring makes oxandrolone resistant to inactivation by 3α-hydroxysteroid dehydrogenase in skeletal muscle. This contrasts with DHT and is believed to underlie oxandrolone's preserved anabolic activity.
As oxandrolone is 5α-reduced, it is not a substrate for aromatase and therefore cannot be converted into metabolites with estrogenic activity. Oxandrolone also lacks progestogenic activity.
Oxandrolone is uniquely less hepatotoxic than other 17α-alkylated AAS, which may be related to differences in metabolism (The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety).
The oral bioavailability of oxandrolone is 97%. Its plasma protein binding ranges from 94% to 97%. The drug is metabolized primarily by the kidneys and to a lesser extent by the liver. Its elimination half-life ranges from 9.4 to 10.4 hours, but is prolonged in the elderly to 13.3 hours. Approximately 28% of an oral oxandrolone dose is excreted unchanged in the urine, and 3% is excreted in the feces (source: OXANDROLONE- oxandrolone tablet).
Chemical Profile
Oxandrolone is a synthetic androstane steroid and a 17α-alkylated derivative of dihydrotestosterone (DHT). It is also known as 2-oxa-17α-methyl-5α-dihydrotestosterone (2-oxa-17α-methyl-DHT) or as 2-oxa-17α-methyl-5α-androstan-17β-ol-3-one. Structurally, it is a DHT molecule with a methyl group at the C17α position and the C2 carbon replaced by an oxygen atom. Oxandrolone was first synthesized by Raphael Pappo and Christopher J. Jung at Searle Laboratories.btw guys i used ai for translation into English so faggots stfu
Shouldn’t I lose weight? 
